Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Nov;60(Suppl 3):iii33–iii36. doi: 10.1136/ard.60.90003.iii33

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α

F Van den Bosch, D Baeten, E Kruithof, F De Keyser, H Mielants, E Veys
PMCID: PMC1766672  PMID: 11890649

Full Text

The Full Text of this article is available as a PDF (114.2 KB).

graphic file with name ard-ppvm.f1.jpg

Open in a new tab

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baeten D., Kruithof E., Van den Bosch F., Demetter P., Van Damme N., Cuvelier C., De Vos M., Mielants H., Veys E. M., De Keyser F. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001 Jan;44(1):186–195. doi: 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  2. Baeten D., Van Damme N., Van den Bosch F., Kruithof E., De Vos M., Mielants H., Veys E. M., De Keyser F. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis. 2001 Aug;60(8):750–755. doi: 10.1136/ard.60.8.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baeten D., Van den Bosch F., Elewaut D., Stuer A., Veys E. M., De Keyser F. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol. 1999;18(6):434–441. doi: 10.1007/s100670050134. [DOI] [PubMed] [Google Scholar]
  4. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., Thriene W., Sieper J., Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000 Jun;43(6):1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  5. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 Apr;38(4):499–505. doi: 10.1002/art.1780380407. [DOI] [PubMed] [Google Scholar]
  6. Charles P. J., Smeenk R. J., De Jong J., Feldmann M., Maini R. N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000 Nov;43(11):2383–2390. doi: 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  7. Clegg D. O., Reda D. J., Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999 Nov;42(11):2325–2329. doi: 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  8. Cuellar M. L., Espinoza L. R. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am. 1997 Nov;23(4):797–809. doi: 10.1016/s0889-857x(05)70361-6. [DOI] [PubMed] [Google Scholar]
  9. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. De Vos M., Mielants H., Cuvelier C., Elewaut A., Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996 Jun;110(6):1696–1703. doi: 10.1053/gast.1996.v110.pm8964393. [DOI] [PubMed] [Google Scholar]
  11. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., Zeidler H., Kvien T. K., Olivieri I., Dijkmans B. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. doi: 10.1002/art.1780380507. [DOI] [PubMed] [Google Scholar]
  12. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., Cats A., Dijkmans B., Olivieri I., Pasero G. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct;34(10):1218–1227. doi: 10.1002/art.1780341003. [DOI] [PubMed] [Google Scholar]
  13. Ellis C. N., Fradin M. S., Messana J. M., Brown M. D., Siegel M. T., Hartley A. H., Rocher L. L., Wheeler S., Hamilton T. A., Parish T. G. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991 Jan 31;324(5):277–284. doi: 10.1056/NEJM199101313240501. [DOI] [PubMed] [Google Scholar]
  14. Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
  15. Knight D. M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moore M. A., Vilcek J., Daddona P. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443–1453. doi: 10.1016/0161-5890(93)90106-l. [DOI] [PubMed] [Google Scholar]
  16. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  17. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  18. Mielants H., Veys E. M., Cuvelier C., De Vos M., Goemaere S., De Clercq L., Schatteman L., Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995 Dec;22(12):2273–2278. [PubMed] [Google Scholar]
  19. Mielants H., Veys E. M., Cuvelier C., de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol. 1988;27 (Suppl 2):95–105. doi: 10.1093/rheumatology/xxvii.suppl_2.95. [DOI] [PubMed] [Google Scholar]
  20. Mielants H., Veys E. M., De Vos M., Cuvelier C., Goemaere S., De Clercq L., Schatteman L., Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995 Dec;22(12):2266–2272. [PubMed] [Google Scholar]
  21. Present D. H., Rutgeerts P., Targan S., Hanauer S. B., Mayer L., van Hogezand R. A., Podolsky D. K., Sands B. E., Braakman T., DeWoody K. L. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398–1405. doi: 10.1056/NEJM199905063401804. [DOI] [PubMed] [Google Scholar]
  22. Smeets T. J., Kraan M. C., Versendaal J., Breedveld F. C., Tak P. P. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol. 1999 Oct;26(10):2089–2093. [PubMed] [Google Scholar]
  23. Spadaro A., Riccieri V., Sili-Scavalli A., Sensi F., Taccari E., Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995 Sep-Oct;13(5):589–593. [PubMed] [Google Scholar]
  24. Targan S. R., Hanauer S. B., van Deventer S. J., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029–1035. doi: 10.1056/NEJM199710093371502. [DOI] [PubMed] [Google Scholar]
  25. Van Hees P. A., Van Lier H. J., Van Elteren P. H., Driessen M., Van Hogezand R. A., Ten Velde G. P., Bakker J. H., Van Tongeren J. H. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut. 1981 May;22(5):404–409. doi: 10.1136/gut.22.5.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Van den Bosch F., Kruithof E., Baeten D., De Keyser F., Mielants H., Veys E. M. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. doi: 10.1136/ard.59.6.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Van den Bosch F., Kruithof E., De Vos M., De Keyser F., Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000 Nov 25;356(9244):1821–1822. doi: 10.1016/s0140-6736(00)03239-6. [DOI] [PubMed] [Google Scholar]
  28. Zeidler H., Mau W., Khan M. A. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am. 1992 Feb;18(1):187–202. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES